BRIEF published on 04/15/2025 at 10:05, 1 year ago IOmx Therapeutics Gains Approval for IOMX-0675 Clinical Trials Immune Response IOmx Therapeutics IOMX-0675 Clinical Trial Approval Solid Tumor Therapy
BRIEF published on 04/15/2025 at 10:05, 1 year ago IOmx Therapeutics obtient l'approbation pour les essais cliniques sur IOMX-0675 Réponse Immunitaire IOmx Therapeutics IOMX-0675 Approbation Des Essais Cliniques Thérapie Des Tumeurs Solides
PRESS RELEASE published on 04/15/2025 at 10:00, 1 year ago iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675 iOmx Therapeutics receives regulatory approval for clinical trial application of IOMX-0675, a LILRB1/LILRB2 dual-targeting antibody, to reverse immune suppression in solid tumors Regulatory Approval Clinical Trial Application IOmx Therapeutics IOMX-0675 Solid Tumor
BRIEF published on 12/19/2024 at 14:05, 1 year 4 months ago IOmx Therapeutics Advances IOMX-0675 with Clinical Trial Application Cancer Treatment Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors
BRIEF published on 12/19/2024 at 14:05, 1 year 4 months ago IOmx Therapeutics fait progresser IOMX-0675 avec une application d'essai clinique Traitement Du Cancer Thérapeutique IOmx IOMX-0675 Demande D'essai Clinique Récepteurs Immunosuppresseurs
PRESS RELEASE published on 12/19/2024 at 14:00, 1 year 4 months ago iOmx Therapeutics submits Clinical Trial Application for IOMX-0675 iOmx Therapeutics submits Clinical Trial Application for IOMX-0675, a dual-targeting antibody demonstrating strong anti-tumor potential by reprogramming myeloid cells and restoring cytotoxic T cell function Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors Anti-tumor Potential
BRIEF published on 08/22/2024 at 10:05, 1 year 7 months ago IOmx Therapeutics Initiates Phase Ib with OMX-0407 Cancer Therapy Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 08/22/2024 at 10:05, 1 year 7 months ago IOmx Therapeutics lance la phase Ib avec OMX-0407 Essai Clinique Thérapie Contre Le Cancer OMX-0407 Phase Ib Thérapeutique IOmx
PRESS RELEASE published on 08/22/2024 at 10:00, 1 year 7 months ago iOmx Therapeutics Initiates Phase Ib with OMX-0407 iOmx Therapeutics initiates Phase Ib clinical trial with OMX-0407, showing favorable safety profile and anti-tumor activity in solid tumors. Expansion phase opens in kidney cancer and angiosarcoma Solid Tumors Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 06/27/2024 at 10:05, 1 year 9 months ago IOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer Chief Financial Officer Biopharmaceutical Leadership IOmx Therapeutics Florian Schmid
Published on 04/21/2026 at 09:05, 1 hour 6 minutes ago Battery X Metals Files International PCT Patent Application for Lithium-Ion Battery Rebalancing Technology, Providing a Pathway to Pursue Patent Protection in 150+ Countries for Technology Validated by a Leading Scientific Institution to Recover ~99% Capa
Published on 04/21/2026 at 05:30, 4 hours 41 minutes ago Battery X Metals Provides Update on Critical Battery Metals Exploration Initiatives and Portfolio Optimization Strategy
Published on 04/21/2026 at 01:05, 9 hours 6 minutes ago Boron One Holdings Inc. Announces Closing of Financing
Published on 04/21/2026 at 00:00, 10 hours 11 minutes ago LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.
Published on 04/21/2026 at 10:05, 6 minutes ago BrightCharger and Endrich sign licensing agreement to expand BrightZero® charging control to new components and products
Published on 04/21/2026 at 10:05, 6 minutes ago ION brings mandatory EU payee verification live at scale
Published on 04/21/2026 at 10:00, 11 minutes ago Karlsberg Brauerei gains further market share in the 2025 financial year
Published on 04/21/2026 at 09:30, 40 minutes ago Original-Research: PFISTERER Holding SE (von GBC AG): BUY
Published on 04/21/2026 at 07:00, 3 hours 11 minutes ago Thales reports its order intake and sales for the first quarter of 2026
Published on 04/21/2026 at 07:00, 3 hours 11 minutes ago Thales publie ses prises de commandes et son chiffre d'affaires du premier trimestre 2026
Published on 04/21/2026 at 06:59, 3 hours 12 minutes ago OPmobility - Chiffre d'affaires du 1er trimestre 2026
Published on 04/20/2026 at 20:44, 13 hours 27 minutes ago ENGIE - Implementation of share buyback programme
